Nakagawa Mio, Ito Kimihiko, Uragami Kiri, Suzuki Junko, Shiomi Mayu, Ono Hitomi, Shimoji Kanoko, Yamashita Michiko, Onoue Masayo, Yoshioka Emi, Goto Mayako, Tashima Lena, Hori Kensuke
Dept. of Obstetrics and Gynecology, Kansai Rosai Hospital.
Gan To Kagaku Ryoho. 2021 Mar;48(3):375-378.
Ovarian clear cell carcinoma(OCCC)shows a poor response to standard chemotherapy, and it is often difficult to choose a regimen for patients with recurrent OCCC. Several reports have suggested a synergistic effect between gemcitabine and cisplatin; another report suggested that gemcitabine, platinum, and bevacizumab are efficacious against recurrent ovarian cancer. We treated patients with OCCC using a combination chemotherapy regimen consisting of gemcitabine(1,000 mg/ m2)and cisplatin(40 mg/m2)on days 1 and 15, and bevacizumab(15 mg/kg)on day 1, with the cycle repeated every 4 weeks. Six patients received this therapy after informed consent, and 2 evaluable patients showed a partial response. Adverse events were mild, with Grade 3 anemia, leukopenia, and neutropenia occurring in 67%, 33%, and 17% of cases, respectively. No Grade 4 events were observed, including hematological or non-hematological toxicities. This suggests that a regimen of combined gemcitabine, platinum, and bevacizumab can be efficacious and feasible for the treatment of OCCC.
卵巢透明细胞癌（OCCC）对标准化疗反应不佳，对于复发性OCCC患者，通常很难选择合适的治疗方案。有几份报告提示吉西他滨和顺铂之间存在协同作用；另一份报告表明，吉西他滨、铂类和贝伐单抗对复发性卵巢癌有效。我们采用一种联合化疗方案治疗OCCC患者，具体为在第1天和第15天使用吉西他滨（1000mg/m²）和顺铂（40mg/m²），在第1天使用贝伐单抗（15mg/kg），每4周重复一个周期。6例患者在签署知情同意书后接受了该治疗，2例可评估患者显示部分缓解。不良事件较轻，3/4级贫血、白细胞减少和中性粒细胞减少分别发生在67%、33%和17%的病例中。未观察到4级事件，包括血液学或非血液学毒性。这表明吉西他滨、铂类和贝伐单抗联合方案对OCCC的治疗可能有效且可行。
